Stockhub

TaiGen Biopharmaceuticals Holdings Limited: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

20 August 2022

14 August 2022

9 August 2022

  • curprev 01:1801:18, 9 August 2022 >Paris 749 bytes +749 Created page with "TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections. It is also developing Taigexyn for treating community-acquired pneumonia and diabetic foot infection, as well as other bacterial infections; Burixafor, a stem cell mobilizer for stem cell transplantation and che..."
Retrieved from "https://stockhub.co/research/TaiGen_Biopharmaceuticals_Holdings_Limited"